The Investigators will investigate the efficacy of combining the standalone iStent infinite and iDose that are minimally invasive surgical and drug depot options are a safe and effective alternative to filtering surgery for intraocuar pressure reduction in patients with medically uncontrolled open angle glaucoma.
The Investigators will assess the mean intraocular pressure change from baseline, the change in the number of medications from baseline, the proportion of patients needing additional incisional surgery, and the incidence of adverse events. The Investigators hypothesize that patients receiving the combined standalone iStent infinite and iDose will experience a safe and significant reduction in mean intraocular pressure and number of medications during the study time period.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Enrollment
20
surgery perfomed using the iStent infinite trabecular micro-bypass system model iS3
surgery performed using the iDose TR (Travoprost intracameral Implant) 75mcg
Wills Eye Hosital Glaucoma Dept.
Philadelphia, Pennsylvania, United States
RECRUITINGIOP reduction from baseline
a logistic regression model will be used for the imputation of missing values, using the 12-month performance outcome as dependent variable, and sex, race, age, baseline IOP, number of IOP-lowering medications used at baseline, last IOP and number of medications at the 6-month visit or later as explanatory variables.
Time frame: Diurnal IOP reduction from baseline at 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.